The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer

被引:95
作者
McKeown, DJ
Brown, DJF
Kelly, A
Wallace, AM
McMillan, DC [1 ]
机构
[1] Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland
[2] Royal Infirm, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland
关键词
inflammatory cytokines; cytokine receptors; C-reactive protein; non-small-cell lung cancer;
D O I
10.1038/sj.bjc.6602248
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between circulating C-reactive protein concentrations and potential cytokine and receptor mediators (interleukin-6, leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), soluble IL-6 receptor, soluble gp130, soluble TNF receptor, interleukin-1 receptor antagonist and interleukin-8 (IL-8)) of this acute phase protein were examined in healthy subjects (n = 11) and patients with non-small-cell lung cancer ( n = 50). Leukaemia inhibitory factor and CNTF were below detection limits in all controls and patients. C-reactive protein, interleukin-6, soluble gp130, soluble TNF receptor, interleukin-1 receptor antagonist and IL-8 concentrations were significantly elevated in cancer patients ( Pless than or equal to0.001). Cancer patients with elevated C-reactive protein concentrations had greater concentrations of interleukin-6 ( P<0.01) and interleukin-1 receptor antagonist ( P<0.05). On regression analysis only interleukin-6 was independently associated with C-reactive protein ( r = 0.616, P<0.001). Interleukin-6 is an important independent mediator of elevated C-reactive protein concentrations in patients with non-small-cell lung cancer.
引用
收藏
页码:1993 / 1995
页数:3
相关论文
共 19 条
[1]  
Alexandrakis MG, 2000, ONCOL REP, V7, P1327
[2]  
BAUMANN H, 1993, J BIOL CHEM, V268, P8414
[3]   Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer [J].
Forrest, LM ;
McMillan, DC ;
McArdle, CS ;
Angerson, WJ ;
Dunlop, DJ .
BRITISH JOURNAL OF CANCER, 2004, 90 (09) :1704-1706
[4]   Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer [J].
Forrest, LM ;
McMillan, DC ;
McArdle, CS ;
Angerson, WJ ;
Dunlop, DJ .
BRITISH JOURNAL OF CANCER, 2003, 89 (06) :1028-1030
[5]   Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway [J].
Heinrich, PC ;
Behrmann, I ;
Müller-Newen, G ;
Schaper, F ;
Graeve, L .
BIOCHEMICAL JOURNAL, 1998, 334 :297-314
[6]   A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease [J].
Ito, H ;
Takazoe, M ;
Fukuda, Y ;
Hibi, T ;
Kusugami, K ;
Andoh, A ;
Matsumoto, T ;
Yamamura, T ;
Azuma, J ;
Nishimoto, N ;
Yoshizaki, K ;
Shimoyama, T ;
Kishimoto, T .
GASTROENTEROLOGY, 2004, 126 (04) :989-996
[7]   The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex [J].
Jones, SA ;
Rose-John, S .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2002, 1592 (03) :251-263
[8]  
LUNDHOLM K, 1994, CANCER RES, V54, P5602
[9]   A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss [J].
McMillan, DC ;
Wigmore, SJ ;
Fearon, KCH ;
O'Gorman, P ;
Wright, CE ;
McArdle, CS .
BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) :495-500
[10]  
MORI M, 1991, CANCER RES, V51, P6656